CLAIMS

1. An antibody or an antigen binding fragment thereof which binds to TRPV1, wherein said antibody or antigen binding fragment thereof binds to TRPV1 in the extracellular region of TRPV1 and wherein said antibody or antigen binding fragment thereof preferentially inhibits capsaicin-induced activation of TRPV1 as opposed to heat-induced activation of TRPV1 as determined when the antibody or antigen binding fragment thereof is used at the same concentration in an assay to determine the level of inhibition of capsaicin-induced activation of TRPV1 as is used in an assay to determine the level of inhibition of heat-induced activation of TRPV1, and wherein said antibody or antigen binding fragment thereof binds to an isolated peptide, said isolated peptide consisting of an amino acid sequence selected from the group consisting of: SEQ ID NO:17, SEQ ID NO:16 and SEQ ID NO:18.

2. The antibody or antigen binding fragment thereof of claim 1, wherein said antibody or antigen binding fragment thereof binds to TRPV1 at an epitope that is in the region defined by amino acid residues 599-630.

3. The antibody or antigen binding fragment thereof of claim 1 or claim 2, wherein said isolated peptides are linear peptides or cyclic peptides.

4. The antibody or antigen binding fragment thereof of any one of claims 1 to 3, wherein said antibody or antigen binding fragment thereof comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein

(i) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:77, a VH CDR2 that has the amino acid sequence of SEQ ID NO:78 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:79, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:80, a VL CDR2 that has the amino acid sequence of SEQ ID NO:81 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:82, or sequences substantially homologous thereto;

(ii) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:41, a VH CDR2 that has the amino acid sequence of SEQ ID NO:42 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:43, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:44, a VL CDR2 that has the amino acid sequence of SEQ ID NO:45 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:46, or sequences substantially homologous thereto;

(iii) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:103, a VH CDR2 that has the amino acid sequence of SEQ ID NO:104 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:105, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:106, a VL CDR2 that has the amino acid sequence of SEQ ID NO:107 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:108, or sequences substantially homologous thereto;

(iv) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:123, a VH CDR2 that has the amino acid sequence of SEQ ID NO:124 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:125, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:126, a VL CDR2 that has the amino acid sequence of SEQ ID NO:127 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:128, or sequences substantially homologous thereto;

(v) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:143, a VH CDR2 that has the amino acid sequence of SEQ ID NO:144 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:145, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:146, a VL CDR2 that has the amino acid sequence of SEQ ID NO:147 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:148, or sequences substantially homologous thereto;

(vi) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:183, a VH CDR2 that has the amino acid sequence of SEQ ID NO:184 and a VH CDR3 that has the amino acid

sequence of SEQ ID NO:185, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:186, a VL CDR2 that has the amino acid sequence of SEQ ID NO:187 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:188, or sequences substantially homologous thereto;

(vii) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:203, a VH CDR2 that has the amino acid sequence of SEQ ID NO:204 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:205, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:206, a VL CDR2 that has the amino acid sequence of SEQ ID NO:207 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:208, or sequences substantially homologous thereto;

(viii) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:223, a VH CDR2 that has the amino acid sequence of SEQ ID NO:224 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:225, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:226, a VL CDR2 that has the amino acid sequence of SEQ ID NO:227 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:228, or sequences substantially homologous thereto;

(ix) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:283, a VH CDR2 that has the amino acid sequence of SEQ ID NO:284 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:285, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:286, a VL CDR2 that has the amino acid sequence of SEQ ID NO:287 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:288, or sequences substantially homologous thereto;

(x) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:303, a VH CDR2 that has the amino acid sequence of SEQ ID NO:304 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:305, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:306, a VL CDR2 that has the amino acid

sequence of SEQ ID NO:307 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:308, or sequences substantially homologous thereto;

(xi) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:323, a VH CDR2 that has the amino acid sequence of SEQ ID NO:324 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:325, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:326, a VL CDR2 that has the amino acid sequence of SEQ ID NO:327 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:328, or sequences substantially homologous thereto; or

(xii) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:363, a VH CDR2 that has the amino acid sequence of SEQ ID NO:364 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:365, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:366, a VL CDR2 that has the amino acid sequence of SEQ ID NO:367 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:368, or sequences substantially homologous thereto,

wherein said substantially homologous sequences are sequences containing 1, 2 or 3 amino acid substitutions compared to the given CDR sequences, or said substantially homologous sequence is a sequence containing conservative amino acid substitutions of the given CDR sequences.

5. The antibody or antigen binding fragment thereof of any one of claims 1 to 4, wherein said antibody or antigen binding fragment thereof comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein

(i) the light chain variable region has the amino acid sequence of SEQ ID NO:76, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:75, or a sequence having at least 80% sequence identity thereto;

(ii) the light chain variable region has the amino acid sequence of SEQ ID NO:58, or a sequence having at least 80% sequence identity thereto and/or wherein

the heavy chain variable region has the amino acid sequence of SEQ ID NO:57, or a sequence having at least 80% sequence identity thereto;

(iii) the light chain variable region has the amino acid sequence of SEQ ID NO:40, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:39, or a sequence having at least 80% sequence identity thereto;

(iv) the light chain variable region has the amino acid sequence of SEQ ID NO:102, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:101, or a sequence having at least 80% sequence identity thereto;

(v) the light chain variable region has the amino acid sequence of SEQ ID NO:122, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:121, or a sequence having at least 80% sequence identity thereto;

(vi) the light chain variable region has the amino acid sequence of SEQ ID NO:142, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:141, or a sequence having at least 80% sequence identity thereto;

(vii) the light chain variable region has the amino acid sequence of SEQ ID NO:162, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:161, or a sequence having at least 80% sequence identity thereto;

(viii) the light chain variable region has the amino acid sequence of SEQ ID NO:182, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:181, or a sequence having at least 80% sequence identity thereto;

(ix) the light chain variable region has the amino acid sequence of SEQ ID NO:202, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:201, or a sequence having at least 80% sequence identity thereto;

(x) the light chain variable region has the amino acid sequence of SEQ ID NO:222, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:221, or a sequence having at least 80% sequence identity thereto;

(xi) the light chain variable region has the amino acid sequence of SEQ ID NO:242, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:241, or a sequence having at least 80% sequence identity thereto;

(xii) the light chain variable region has the amino acid sequence of SEQ ID NO:262, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:261, or a sequence having at least 80% sequence identity thereto;

(xiii) the light chain variable region has the amino acid sequence of SEQ ID NO:282, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:281, or a sequence having at least 80% sequence identity thereto;

(xiv) the light chain variable region has the amino acid sequence of SEQ ID NO:302, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:301, or a sequence having at least 80% sequence identity thereto;

(xv) the light chain variable region has the amino acid sequence of SEQ ID NO:322, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:321, or a sequence having at least 80% sequence identity thereto;

(xvi) the light chain variable region has the amino acid sequence of SEQ ID NO:362, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:361, or a sequence having at least 80% sequence identity thereto;

(xvii) the light chain variable region has the amino acid sequence of SEQ ID NO:382, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:381, or a sequence having at least 80% sequence identity thereto; or

(xviii) the light chain variable region has the amino acid sequence of SEQ ID NO:402, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:401, or a sequence having at least 80% sequence identity thereto.

6. The antibody or antigen binding fragment thereof of any one of claims 1 to 3, wherein said antibody or antigen binding fragment thereof comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:343, a VH CDR2 that has the amino acid sequence of SEQ ID NO:344 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:345, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:346, a VL CDR2 that has the amino acid sequence of SEQ ID NO:347 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:348, or sequences substantially homologous thereto, wherein said substantially homologous sequences are sequences containing 1, 2 or 3 amino acid substitutions compared to the given CDR sequences, or said substantially homologous sequences are sequences containing conservative amino acid substitutions of the given CDR sequences.

7. The antibody or antigen binding fragment thereof of any one of claims 1 to 3 or claim 6, wherein said antibody or antigen binding fragment thereof comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein the light chain variable region has the amino acid sequence of SEQ ID NO:342, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:341, or a sequence having at least 80% sequence identity thereto.

8. The antibody or antigen binding fragment thereof of any one of claims 1 to 3, wherein said antibody or antigen binding fragment thereof comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:423, a VH CDR2 that has the amino acid sequence of SEQ ID NO:424 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:425, or sequences substantially homologous thereto, and/or wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:426, a VL CDR2 that has the amino acid sequence of SEQ ID NO:427 and a VL

CDR3 that has the amino acid sequence of SEQ ID NO:428, or sequences substantially homologous thereto, wherein said substantially homologous sequences are sequences containing 1, 2 or 3 amino acid substitutions compared to the given CDR sequences, or said substantially homologous sequences are sequences containing conservative amino acid substitutions of the given CDR sequences.

9. The antibody or antigen binding fragment thereof of any one of claims 1 to 3 or claim 8, wherein said antibody or antigen binding fragment thereof comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein the light chain variable region has the amino acid sequence of SEQ ID NO:422, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:421, or a sequence having at least 80% sequence identity thereto.

10. The antibody or antigen binding fragment thereof of any one of claims 1 to 9, wherein said antibody is a polyclonal antibody or a monoclonal antibody.

11. A monoclonal antibody or antigen binding fragment thereof which binds to TRPV1, wherein said antibody or antigen binding fragment thereof inhibits capsaicin-induced activation of TRPV1, wherein said antibody or antigen binding fragment thereof binds to an epitope of TRPV1 in the region of TRPV1 defined by amino acid residues 599-630 of TRPV1 (SEQ ID NO:1), and wherein said antibody or antigen binding fragment thereof binds to an isolated peptide, said isolated peptide consisting of an amino acid sequence selected from the group consisting of: SEQ ID NO:17, SEQ ID NO:16 and SEQ ID NO:18.

12. The monoclonal antibody or antigen binding fragment thereof of claim 11, wherein said antibody or antigen binding fragment thereof comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein said heavy chain variable region and said light chain variable region are as defined in any one of claims 4 to 9.

13. A monoclonal antibody or antigen binding fragment thereof which binds to TRPV1, wherein said antibody or antigen binding fragment thereof

(a) comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein

(i) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:77, a VH CDR2 that has the amino acid sequence of SEQ ID NO:78 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:79, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:80, a VL CDR2 that has the amino acid sequence of SEQ ID NO:81 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:82;

(ii) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:41, a VH CDR2 that has the amino acid sequence of SEQ ID NO:42 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:43, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:44, a VL CDR2 that has the amino acid sequence of SEQ ID NO:45 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:46;

(iii) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:103, a VH CDR2 that has the amino acid sequence of SEQ ID NO:104 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:105, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:106, a VL CDR2 that has the amino acid sequence of SEQ ID NO:107 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:108;

(iv) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:123, a VH CDR2 that has the amino acid sequence of SEQ ID NO:124 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:125, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:126, a VL CDR2 that has the amino acid sequence of SEQ ID NO:127 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:128;

(v) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:143, a VH CDR2 that has the amino acid sequence of SEQ ID NO:144 and a VH CDR3 that has the amino acid

sequence of SEQ ID NO:145, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:146, a VL CDR2 that has the amino acid sequence of SEQ ID NO:147 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:148;

(vi) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:183, a VH CDR2 that has the amino acid sequence of SEQ ID NO:184 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:185, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:186, a VL CDR2 that has the amino acid sequence of SEQ ID NO:187 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:188;

(vii) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:203, a VH CDR2 that has the amino acid sequence of SEQ ID NO:204 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:205, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:206, a VL CDR2 that has the amino acid sequence of SEQ ID NO:207 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:208;

(viii) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:223, a VH CDR2 that has the amino acid sequence of SEQ ID NO:224 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:225, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:226, a VL CDR2 that has the amino acid sequence of SEQ ID NO:227 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:228;

(ix) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:283, a VH CDR2 that has the amino acid sequence of SEQ ID NO:284 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:285, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:286, a VL CDR2 that has the amino acid sequence of SEQ ID NO:287 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:288;

(x) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:303, a VH CDR2 that has the amino acid sequence of SEQ ID NO:304 and a VH CDR3 that has the amino acid

sequence of SEQ ID NO:305, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:306, a VL CDR2 that has the amino acid sequence of SEQ ID NO:307 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:308;

(xi) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:323, a VH CDR2 that has the amino acid sequence of SEQ ID NO:324 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:325, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:326, a VL CDR2 that has the amino acid sequence of SEQ ID NO:327 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:328;

(xii) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:363, a VH CDR2 that has the amino acid sequence of SEQ ID NO:364 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:365, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:366, a VL CDR2 that has the amino acid sequence of SEQ ID NO:367 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:368;

(xiii) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:343, a VH CDR2 that has the amino acid sequence of SEQ ID NO:344 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:345, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:346, a VL CDR2 that has the amino acid sequence of SEQ ID NO:347 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:348; or

(xiv) said heavy chain variable region comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:423, a VH CDR2 that has the amino acid sequence of SEQ ID NO:424 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:425, and wherein said light chain variable region comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:426, a VL CDR2 that has the amino acid sequence of SEQ ID NO:427 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:428, or

(b) has the ability to compete with an antibody or antigen binding fragment thereof as defined in (a) for binding to TRPV1.

14. The monoclonal antibody or antigen binding fragment thereof of claim 13, wherein (a)

(i) the light chain variable region has the amino acid sequence of SEQ ID NO:76, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:75, or a sequence having at least 80% sequence identity thereto;

(ii) the light chain variable region has the amino acid sequence of SEQ ID NO:58, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:57, or a sequence having at least 80% sequence identity thereto;

(iii) the light chain variable region has the amino acid sequence of SEQ ID NO:40, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:39, or a sequence having at least 80% sequence identity thereto;

(iv) the light chain variable region has the amino acid sequence of SEQ ID NO:102, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:101, or a sequence having at least 80% sequence identity thereto;

(v) the light chain variable region has the amino acid sequence of SEQ ID NO:122, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:121, or a sequence having at least 80% sequence identity thereto;

(vi) the light chain variable region has the amino acid sequence of SEQ ID NO:142, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:141, or a sequence having at least 80% sequence identity thereto;

(vii) the light chain variable region has the amino acid sequence of SEQ ID NO:162, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:161, or a sequence having at least 80% sequence identity thereto;

(viii) the light chain variable region has the amino acid sequence of SEQ ID NO:182, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:181, or a sequence having at least 80% sequence identity thereto;

(ix) the light chain variable region has the amino acid sequence of SEQ ID NO:202, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:201, or a sequence having at least 80% sequence identity thereto;

(x) the light chain variable region has the amino acid sequence of SEQ ID NO:222, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:221, or a sequence having at least 80% sequence identity thereto;

(xi) the light chain variable region has the amino acid sequence of SEQ ID NO:242, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:241, or a sequence having at least 80% sequence identity thereto;

(xii) the light chain variable region has the amino acid sequence of SEQ ID NO:262, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:261, or a sequence having at least 80% sequence identity thereto;

(xiii) the light chain variable region has the amino acid sequence of SEQ ID NO:282, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:281, or a sequence having at least 80% sequence identity thereto;

(xiv) the light chain variable region has the amino acid sequence of SEQ ID NO:302, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:301, or a sequence having at least 80% sequence identity thereto;

(xv) the light chain variable region has the amino acid sequence of SEQ ID NO:322, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:321, or a sequence having at least 80% sequence identity thereto;

(xvi) the light chain variable region has the amino acid sequence of SEQ ID NO:362, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:361, or a sequence having at least 80% sequence identity thereto;

(xvii) the light chain variable region has the amino acid sequence of SEQ ID NO:382, or a sequence having at least 80% sequence identity thereto and/or

wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:381, or a sequence having at least 80% sequence identity thereto;

(xviii) the light chain variable region has the amino acid sequence of SEQ ID NO:402, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:401, or a sequence having at least 80% sequence identity thereto;

(xix) the light chain variable region has the amino acid sequence of SEQ ID NO:342, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:341, or a sequence having at least 80% sequence identity thereto; or

(xx) the light chain variable region has the amino acid sequence of SEQ ID NO:422, or a sequence having at least 80% sequence identity thereto and/or wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:421, or a sequence having at least 80% sequence identity thereto, or

wherein (b) said antibody or antigen binding fragment thereof has the ability to compete with an antibody or antigen binding fragment thereof of (a) for binding to TRPV1.

15. The antibody of any one of claims 1 to 14, wherein said antibody is a whole antibody comprising an antibody constant region.

16. The antibody of any one of claims 1 to 15, wherein said antibody is an IgG antibody.

17. A composition comprising an antibody or antigen binding fragment thereof of any one of claims 1 to 16 and a diluent, carrier or excipient.

18. The composition of claim 17, wherein said diluent, carrier or excipient is a pharmaceutically acceptable diluent, carrier or excipient.

19. A nucleic acid molecule comprising a nucleotide sequence that encodes an antibody or antigen binding fragment thereof of any one of claims 1 to 18, or a set of nucleic acid molecules each comprising a nucleotide sequence, wherein said set of nucleic

acid molecules together encode an antibody or antigen binding fragment thereof of any one of claims 1 to 18.

20. A method of producing an antibody or antigen binding fragment thereof according to any one of claims 1 to 18, comprising the steps of:

(i) culturing a host cell comprising (i) one or more nucleic acid molecules encoding an antibody or antigen binding fragment thereof according to any one of claims 1 to 18 or (ii) a set of nucleic acid molecules each comprising a nucleotide sequence, wherein said set of nucleic acid molecules together encode an antibody or antigen binding fragment thereof of any one of claims 1 to 18, or (iii) one or more recombinant expression vectors comprising one or more of said nucleic acid molecules, under conditions suitable for the expression of the encoded antibody or antigen binding fragment thereof; and

(ii) isolating or obtaining the antibody or antigen binding fragment thereof from the host cell or from the growth medium/supernatant.

21. An antibody or antigen binding fragment thereof as defined in any one of claims 1 to 18 for use in therapy.

22. An antibody or antigen binding fragment thereof as defined in any one of claims 1 to 18 for use in pain therapy.

23. Use of an antibody or antigen binding fragment thereof as defined in any one of claims 1 to 18 in the manufacture of a medicament for use in therapy.

24. The use according to claim 23, wherein said therapy is the treatment of pain.